Early TAVR or SAVR for asymptomatic severe AS limits strokes, hospitalizations.
Early TAVR or SAVR for asymptomatic severe AS limits strokes, hospitalizations.
The study titled “Early Aortic Valve Replacement in Asymptomatic Severe Aortic Stenosis: A Meta-Analysis of Randomized Controlled Trials” by Sameena K. Brar et al. was published in the American Journal of Cardiology on March 7, 2025.
Key Findings:
• Unplanned Hospitalizations: Early AVR significantly reduced the risk of unplanned hospitalizations (HR 0.42, 95% CI 0.33–0.53, p < 0.001, I² = 0%).
• All-Cause Mortality: There was a trend towards reduced all-cause mortality with early AVR, though it did not reach statistical significance (HR 0.76, 95% CI 0.48–1.21, I² = 42%).
• Stroke Incidence: Stroke rates also trended lower with early AVR (HR 0.63, 95% CI 0.40–1.00, p = 0.05, I² = 0%).
These findings suggest that early AVR may offer clinical benefits by reducing adverse events, particularly unplanned rehospitalizations, in patients with asymptomatic severe AS. The authors propose that early AVR could be advantageous and recommend considering these results in future guideline updates.
